Latest / Investopedia Markets News (all except PF)
Novo Nordisk Stock Sinks on Disappointing Heart Drug Trial Results
Novo Nordisk’s U.S.-listed shares entered Friday up 1% this year.Credit: Michal Cizek / AFP via Getty ImagesKey TakeawaysNovo Nordisk’s U.S.-listed shares fell premarket after disappointing heart drug trial results.The Phase 3 trial showed the heart drug ziltivekimab failed to reduce cardiovascular risks.U.S.-listed shares of Novo Nordisk closed Thursday up just 1% this year. They look likely to drop into the red today.Novo Nordisk’s (NVO) U.S.-listed shares were sinking about 9% premarket after the Danish pharmaceutical firm said its heart drug ziltivekimab, aimed at inflammatory conditions…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.